Eloxx reports Q3 net loss of $3.6M; positive Phase 2 data for ELX-02; Nasdaq delisting appeal pending

Eloxx Pharmaceuticals, Inc.

2023-Q3 EPS reported -$5.96 vs consensus -$2.01 ▼ miss (-196.6%)

Net loss of $3.6M ($1.31/share) vs. $7.5M loss a year ago; R&D expenses down to $1.3M from $4.9M.
Cash of $4.8M as of Sep 30; raised $3.8M in Q3; cash expected to fund operations only through end of Q4 2023.
Phase 2 open-label trial of ELX-02 in Alport Syndrome showed improved kidney morphology, collagen expression, and average 60% increase in filtration slit density.
Strategic partnership progress for ZKN-013; FDA clearance received for single ascending dose trial.
Common stock suspended on Nasdaq on Oct 16 and now trades on OTC Pink; appeal of delisting decision pending.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eloxx Pharmaceuticals, Inc. reported third fiscal quarter ended September 30, 2023 results: net income $3.6 million, EPS $1.31 per share.

Period: third fiscal quarter ended September 30, 2023
Net income: $3.6 million
EPS: $1.31 per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2023, we incurred a net loss of $3.6 million, or $1.31 per share

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-117308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.